Health
New head lice treatment approved for use in USA – Mirage News
L – R Hatchtech CEO Hugh Alsop, Associate Professor Vern Bowles and Hatchtech Chairman Paul Kelly. Photo: supplied. A new prescription head lice…
L – R Hatchtech CEO Hugh Alsop, Associate Professor Vern Bowles and Hatchtech Chairman Paul Kelly. Photo: supplied.
A new prescription head lice treatment, developed by University of Melbourne Associate Professor Vern Bowles, has been given Food and Drug Administration (FDA) approval, allowing it to be sold in the USA.
The treatment, Xeglyze™, was developed by Hatchtech, an Australian pharmaceutical company and will be commercialised by Dr Reddy’s Laboratories.
Hatchtech CEO Hugh Alsop estim…
Continue Reading